First known person-to-person transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in the USA.


Journal

Lancet (London, England)
ISSN: 1474-547X
Titre abrégé: Lancet
Pays: England
ID NLM: 2985213R

Informations de publication

Date de publication:
04 04 2020
Historique:
received: 02 03 2020
revised: 06 03 2020
accepted: 06 03 2020
pubmed: 18 3 2020
medline: 10 4 2020
entrez: 18 3 2020
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in China in December, 2019. In January, 2020, state, local, and federal public health agencies investigated the first case of COVID-19 in Illinois, USA. Patients with confirmed COVID-19 were defined as those with a positive SARS-CoV-2 test. Contacts were people with exposure to a patient with COVID-19 on or after the patient's symptom onset date. Contacts underwent active symptom monitoring for 14 days following their last exposure. Contacts who developed fever, cough, or shortness of breath became persons under investigation and were tested for SARS-CoV-2. A convenience sample of 32 asymptomatic health-care personnel contacts were also tested. Patient 1-a woman in her 60s-returned from China in mid-January, 2020. One week later, she was hospitalised with pneumonia and tested positive for SARS-CoV-2. Her husband (Patient 2) did not travel but had frequent close contact with his wife. He was admitted 8 days later and tested positive for SARS-CoV-2. Overall, 372 contacts of both cases were identified; 347 underwent active symptom monitoring, including 152 community contacts and 195 health-care personnel. Of monitored contacts, 43 became persons under investigation, in addition to Patient 2. These 43 persons under investigation and all 32 asymptomatic health-care personnel tested negative for SARS-CoV-2. Person-to-person transmission of SARS-CoV-2 occurred between two people with prolonged, unprotected exposure while Patient 1 was symptomatic. Despite active symptom monitoring and testing of symptomatic and some asymptomatic contacts, no further transmission was detected. None.

Sections du résumé

BACKGROUND
Coronavirus disease 2019 (COVID-19) is a disease caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), first detected in China in December, 2019. In January, 2020, state, local, and federal public health agencies investigated the first case of COVID-19 in Illinois, USA.
METHODS
Patients with confirmed COVID-19 were defined as those with a positive SARS-CoV-2 test. Contacts were people with exposure to a patient with COVID-19 on or after the patient's symptom onset date. Contacts underwent active symptom monitoring for 14 days following their last exposure. Contacts who developed fever, cough, or shortness of breath became persons under investigation and were tested for SARS-CoV-2. A convenience sample of 32 asymptomatic health-care personnel contacts were also tested.
FINDINGS
Patient 1-a woman in her 60s-returned from China in mid-January, 2020. One week later, she was hospitalised with pneumonia and tested positive for SARS-CoV-2. Her husband (Patient 2) did not travel but had frequent close contact with his wife. He was admitted 8 days later and tested positive for SARS-CoV-2. Overall, 372 contacts of both cases were identified; 347 underwent active symptom monitoring, including 152 community contacts and 195 health-care personnel. Of monitored contacts, 43 became persons under investigation, in addition to Patient 2. These 43 persons under investigation and all 32 asymptomatic health-care personnel tested negative for SARS-CoV-2.
INTERPRETATION
Person-to-person transmission of SARS-CoV-2 occurred between two people with prolonged, unprotected exposure while Patient 1 was symptomatic. Despite active symptom monitoring and testing of symptomatic and some asymptomatic contacts, no further transmission was detected.
FUNDING
None.

Identifiants

pubmed: 32178768
pii: S0140-6736(20)30607-3
doi: 10.1016/S0140-6736(20)30607-3
pmc: PMC7158585
pii:
doi:

Types de publication

Case Reports Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

1137-1144

Investigateurs

Sarah Brister (S)
Kristin Goldesberry (K)
Stacey Hoferka (S)
Dejan Jovanov (D)
Dawn Nims (D)
Lori Saathoff-Huber (L)
Chantel Hoskin Snelling (C)
Hira Adil (H)
Raabiah Ali (R)
Elaina Andreychak (E)
Kelley Bemis (K)
Mabel Frias (M)
Pearl Quartey-Kumapley (P)
Kristin Baskerville (K)
Elizabeth Murphy (E)
Emily Murskyj (E)
Zach Noffsinger (Z)
Janice Vercillo (J)
Apryll Elliott (A)
Uche S Onwuta (US)
Danielle Burck (D)
Glen Abedi (G)
Rachel M Burke (RM)
Ryan Fagan (R)
Jennifer Farrar (J)
Alicia M Fry (AM)
Aron J Hall (AJ)
Amber Haynes (A)
Connor Hoff (C)
Shifaq Kamili (S)
Marie E Killerby (ME)
Lindsay Kim (L)
Stephanie A Kujawski (SA)
David T Kuhar (DT)
Brian Lynch (B)
Lakshmi Malapati (L)
Mariel Marlow (M)
Janná R Murray (JR)
Brian Rha (B)
Senthil Kumar K Sakthivel (SKK)
Sarah E Smith-Jeffcoat (SE)
Elizabeth Soda (E)
Lijuan Wang (L)
Brett L Whitaker (BL)
Timothy M Uyeki (TM)

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 Elsevier Ltd. All rights reserved.

Références

Lancet. 2020 Feb 15;395(10223):514-523
pubmed: 31986261
Lancet. 2020 Feb 22;395(10224):565-574
pubmed: 32007145
N Engl J Med. 2020 Mar 26;382(13):1199-1207
pubmed: 31995857
Emerg Infect Dis. 2004 Feb;10(2):256-60
pubmed: 15030693
N Engl J Med. 2020 Mar 5;382(10):929-936
pubmed: 32004427
BMC Med. 2015 Sep 03;13:210
pubmed: 26336062
Lancet. 2020 Feb 15;395(10223):507-513
pubmed: 32007143
J R Soc Interface. 2020 Jul;17(168):20200144
pubmed: 32693748
N Engl J Med. 2020 Feb 27;382(9):872-874
pubmed: 31991079
Euro Surveill. 2015 Jun 25;20(25):7-13
pubmed: 26132767

Auteurs

Isaac Ghinai (I)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Illinois Department of Public Health, Springfield, IL, USA.

Tristan D McPherson (TD)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Chicago Department of Public Health, Chicago, IL, USA. Electronic address: oko9@cdc.gov.

Jennifer C Hunter (JC)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Hannah L Kirking (HL)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Demian Christiansen (D)

Cook County Department of Public Health, Oak Forest, IL, USA.

Kiran Joshi (K)

Cook County Department of Public Health, Oak Forest, IL, USA.

Rachel Rubin (R)

Cook County Department of Public Health, Oak Forest, IL, USA.

Shirley Morales-Estrada (S)

Cook County Department of Public Health, Oak Forest, IL, USA.

Stephanie R Black (SR)

Chicago Department of Public Health, Chicago, IL, USA.

Massimo Pacilli (M)

Chicago Department of Public Health, Chicago, IL, USA.

Marielle J Fricchione (MJ)

Chicago Department of Public Health, Chicago, IL, USA.

Rashmi K Chugh (RK)

DuPage County Health Department, Wheaton, IL, USA.

Kelly A Walblay (KA)

Chicago Department of Public Health, Chicago, IL, USA.

N Seema Ahmed (NS)

Metro Infectious Disease Consultants, Burr Ridge, IL, USA.

William C Stoecker (WC)

Metro Infectious Disease Consultants, Burr Ridge, IL, USA.

Nausheen F Hasan (NF)

Premier Primary Care Physicians, Carol Stream, IL, USA.

Deborah P Burdsall (DP)

Illinois Department of Public Health, Springfield, IL, USA.

Heather E Reese (HE)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Megan Wallace (M)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Chen Wang (C)

Cook County Health, Chicago, IL, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Darcie Moeller (D)

Cook County Health, Chicago, IL, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Jacqueline Korpics (J)

Cook County Health, Chicago, IL, USA; Feinberg School of Medicine, Northwestern University, Chicago, IL, USA.

Shannon A Novosad (SA)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Isaac Benowitz (I)

Division of Healthcare Quality Promotion, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Max W Jacobs (MW)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Lake Erie College of Osteopathic Medicine, Erie, PA, USA.

Vishal S Dasari (VS)

One Health Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA; Boonshoft School of Medicine, Wright State University, Dayton, OH, USA.

Megan T Patel (MT)

Illinois Department of Public Health, Springfield, IL, USA.

Judy Kauerauf (J)

Illinois Department of Public Health, Springfield, IL, USA.

E Matt Charles (EM)

Illinois Department of Public Health, Springfield, IL, USA.

Ngozi O Ezike (NO)

Illinois Department of Public Health, Springfield, IL, USA.

Victoria Chu (V)

Epidemic Intelligence Service, Centers for Disease Control and Prevention, Atlanta, GA, USA; Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Claire M Midgley (CM)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Melissa A Rolfes (MA)

Influenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Susan I Gerber (SI)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Xiaoyan Lu (X)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Stephen Lindstrom (S)

Division of Viral Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Jennifer R Verani (JR)

Division of Bacterial Diseases, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.

Jennifer E Layden (JE)

Chicago Department of Public Health, Chicago, IL, USA. Electronic address: jennifer.layden@cityofchicago.org.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH